Repositioning approved drugs for the treatment of problematic cancers using a screening approach.
Advances in treatment strategies together with an earlier diagnosis have considerably increased the average survival of cancer patients over the last four decades. Nevertheless, despite the growing number of new antineoplastic agents introduced each year, there is still no adequate therapy for probl...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0171052&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133392003170304 |
|---|---|
| author | Hristo P Varbanov Fabien Kuttler Damiano Banfi Gerardo Turcatti Paul J Dyson |
| author_facet | Hristo P Varbanov Fabien Kuttler Damiano Banfi Gerardo Turcatti Paul J Dyson |
| author_sort | Hristo P Varbanov |
| collection | DOAJ |
| description | Advances in treatment strategies together with an earlier diagnosis have considerably increased the average survival of cancer patients over the last four decades. Nevertheless, despite the growing number of new antineoplastic agents introduced each year, there is still no adequate therapy for problematic malignancies such as pancreatic, lung and stomach cancers. Consequently, it is important to ensure that existing drugs used to treat other types of cancers, and potentially other diseases, are not overlooked when searching for new chemotherapy regimens for these problematic cancer types. We describe a screening approach that identifies chemotherapeutics for the treatment of lung and pancreatic cancers, based on drugs already approved for other applications. Initially, the 1280 chemically and pharmacologically diverse compounds from the Prestwick Chemical Library® (PCL) were screened against A549 (lung cancer) and PANC-1 (pancreatic carcinoma) cells using the PrestoBlue fluorescent-based cell viability assay. More than 100 compounds from the PCL were identified as hits in one or both cell lines (80 of them, being drugs used to treat diseases other than cancer). Selected PCL hits were further evaluated in a dose-response manner. Promising candidates for repositioning emanating from this study include antiparasitics, cardiac glycosides, as well as the anticancer drugs vorinostat and topotecan. |
| format | Article |
| id | doaj-art-0db6c7462f61449fbadf9dde6b3b0c4a |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-0db6c7462f61449fbadf9dde6b3b0c4a2025-08-20T02:31:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e017105210.1371/journal.pone.0171052Repositioning approved drugs for the treatment of problematic cancers using a screening approach.Hristo P VarbanovFabien KuttlerDamiano BanfiGerardo TurcattiPaul J DysonAdvances in treatment strategies together with an earlier diagnosis have considerably increased the average survival of cancer patients over the last four decades. Nevertheless, despite the growing number of new antineoplastic agents introduced each year, there is still no adequate therapy for problematic malignancies such as pancreatic, lung and stomach cancers. Consequently, it is important to ensure that existing drugs used to treat other types of cancers, and potentially other diseases, are not overlooked when searching for new chemotherapy regimens for these problematic cancer types. We describe a screening approach that identifies chemotherapeutics for the treatment of lung and pancreatic cancers, based on drugs already approved for other applications. Initially, the 1280 chemically and pharmacologically diverse compounds from the Prestwick Chemical Library® (PCL) were screened against A549 (lung cancer) and PANC-1 (pancreatic carcinoma) cells using the PrestoBlue fluorescent-based cell viability assay. More than 100 compounds from the PCL were identified as hits in one or both cell lines (80 of them, being drugs used to treat diseases other than cancer). Selected PCL hits were further evaluated in a dose-response manner. Promising candidates for repositioning emanating from this study include antiparasitics, cardiac glycosides, as well as the anticancer drugs vorinostat and topotecan.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0171052&type=printable |
| spellingShingle | Hristo P Varbanov Fabien Kuttler Damiano Banfi Gerardo Turcatti Paul J Dyson Repositioning approved drugs for the treatment of problematic cancers using a screening approach. PLoS ONE |
| title | Repositioning approved drugs for the treatment of problematic cancers using a screening approach. |
| title_full | Repositioning approved drugs for the treatment of problematic cancers using a screening approach. |
| title_fullStr | Repositioning approved drugs for the treatment of problematic cancers using a screening approach. |
| title_full_unstemmed | Repositioning approved drugs for the treatment of problematic cancers using a screening approach. |
| title_short | Repositioning approved drugs for the treatment of problematic cancers using a screening approach. |
| title_sort | repositioning approved drugs for the treatment of problematic cancers using a screening approach |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0171052&type=printable |
| work_keys_str_mv | AT hristopvarbanov repositioningapproveddrugsforthetreatmentofproblematiccancersusingascreeningapproach AT fabienkuttler repositioningapproveddrugsforthetreatmentofproblematiccancersusingascreeningapproach AT damianobanfi repositioningapproveddrugsforthetreatmentofproblematiccancersusingascreeningapproach AT gerardoturcatti repositioningapproveddrugsforthetreatmentofproblematiccancersusingascreeningapproach AT pauljdyson repositioningapproveddrugsforthetreatmentofproblematiccancersusingascreeningapproach |